Recommended tactics for mass vaccination of healthy individuals and COVID-19 convalescents

Abstract

This article presents our views on main scientific and methodological approaches regarding the advantages of conducting mass vaccination of healthy individuals and COVID-19 convalescents. First of all, the focus is on issues regarding the antigenic potencies of SARS-CoV-2, based on which vaccines have been created over the past three years that have successfully passed preclinical and clinical testing, as well as licensing. The subjects of specal discussion were aspects related to the short-term effect of the main vaccines, as a result of which revaccination is recommended. It is assumed that more than one antigenic determinant is expressed on the surface of SARS-CoV-2. In the conclusion paragraph, we have presented our own concept on most topical situational issues among the population of many countries in the process of vaccination against COVID-19. Is it worth getting vaccinated at all if complications can arise that lead to disability and death even in practically healthy individuals, not to mention the elderly contingent with chronic diseases? In making a positive decision, the question arises in terms of choosing a vaccine, since vaccines are used in different countries, in the production of which different scientific, methodological and technological approaches are used. If there is a need for re-vaccination within a short period after the first vaccination? As a rule, it is recommended to re-vaccinate in 14-30 days after the first vaccination. In this regard, there are concerns about the low efficacy (weak selective immunogenic activity) of vaccines. How expedient, if not contraindicated, is to “fully” vaccinate patients in the recovery period, as well as over the next one to two months, if they have high levels of SARS-CoV-2 antibodies? In case of re-vaccination, it is necessary to find out whether it is possible to get the second vaccination using a commercial vaccine of another manufacturer, especially since many developing countries do not currently have such a vaccine that has been introduced during the first vaccination. How competent is it to vaccinate a wide range of healthy individuals against COVID-19 and influenza - for the same time or with the shortest time interval?